TORONTO and RIONEGRO, Colombia, Nov. 12, 2020 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian dad or mum of Colombia’s premier cultivator and producer of medicinal-quality hashish oil, PharmaCielo Colombia Holdings S.A.S., introduced today that it will host a convention contact on Monday, November 30th, 2020, at 8:00 a.m. ET to examine its 3rd quarter fiscal benefits and present traders with essential business enterprise highlights. The simply call will be chaired by David Attard, CEO and Scott Laitinen, CFO.
Convention Connect with Information
Day: November 30th, 2020 | Time: 8:00am ET
Participant Dial-in: 416-764-8650 or 1-888-664-6383
Replay Dial-in: 416-764-8677 or 1-888-390-0541
Meeting ID: 60606383
Playback #: 606383 (Expires December 14, 2020)
Listen to webcast: https://produceredition.webcasts.com/starthere.jsp?ei=1402171&tp_essential=1965advertisement980c
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a world wide organization, headquartered in Canada, with a focus on moral and sustainable processing and supplying of all organic, medicinal-grade cannabis oil extracts and linked items to big channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre situated in Rionegro, Colombia.
The board of directors and executive workforce of PharmaCielo are comprised of a diversely talented team of intercontinental small business executives and specialists with applicable and diverse skills. PharmaCielo identified the significant job that Colombia’s ideal place plays in creating a sustainable small business in the medical hashish field, and the Organization, collectively with its directors and executives, is executing on a business enterprise plan targeted on giving the global marketplace.
Neither the TSXV nor its Regulation Providers Service provider (as that phrase is described in the guidelines of the TSXV) accepts duty for the adequacy or precision of this press release.
Resource PharmaCielo Ltd.